These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 23606826)

  • 21. Associations of Perfluoroalkyl substances with blood lipids and Apolipoproteins in lipoprotein subspecies: the POUNDS-lost study.
    Liu G; Zhang B; Hu Y; Rood J; Liang L; Qi L; Bray GA; DeJonge L; Coull B; Grandjean P; Furtado JD; Sun Q
    Environ Health; 2020 Jan; 19(1):5. PubMed ID: 31931806
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Potent and selective PPAR-alpha agonist LY518674 upregulates both ApoA-I production and catabolism in human subjects with the metabolic syndrome.
    Millar JS; Duffy D; Gadi R; Bloedon LT; Dunbar RL; Wolfe ML; Movva R; Shah A; Fuki IV; McCoy M; Harris CJ; Wang MD; Howey DC; Rader DJ
    Arterioscler Thromb Vasc Biol; 2009 Jan; 29(1):140-6. PubMed ID: 18988892
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The effect of aggressive and moderate lowering of LDL-cholesterol and low dose anticoagulation on plasma lipids, apolipoproteins and lipoprotein families in post coronary artery bypass graft trial.
    Alaupovic P; Fesmire JD; Hunnighake D; Domanski M; Forman S; Knatterud GL; Forrester J; Herd JA; Hoogwerf B; Campeau L; Gobel FL
    Atherosclerosis; 1999 Oct; 146(2):369-79. PubMed ID: 10532693
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Tesaglitazar, a novel dual peroxisome proliferator-activated receptor alpha/gamma agonist, dose-dependently improves the metabolic abnormalities associated with insulin resistance in a non-diabetic population.
    Fagerberg B; Edwards S; Halmos T; Lopatynski J; Schuster H; Stender S; Stoa-Birketvedt G; Tonstad S; Halldórsdóttir S; Gause-Nilsson I
    Diabetologia; 2005 Sep; 48(9):1716-25. PubMed ID: 16001233
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Efficacy, safety and tolerability of tesaglitazar when added to the therapeutic regimen of poorly controlled insulin-treated patients with type 2 diabetes.
    Ratner RE; Parikh S; Tou C;
    Diab Vasc Dis Res; 2007 Sep; 4(3):214-21. PubMed ID: 17907111
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effect of thyroid hormone on plasma apolipoproteins and apoA- and apoB-containing lipoprotein particles.
    Liu XQ; Rahman A; Bagdade JD; Alaupovic P; Kannan CR
    Eur J Clin Invest; 1998 Apr; 28(4):266-70. PubMed ID: 9615901
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The relationship between high density lipoprotein subclass profile and apolipoprotein concentrations.
    Tian L; Fu M
    J Endocrinol Invest; 2011 Jun; 34(6):461-72. PubMed ID: 21747218
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Statins for treatment of dyslipidemia in chronic kidney disease.
    Shurraw S; Tonelli M
    Perit Dial Int; 2006; 26(5):523-39. PubMed ID: 16973506
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A novel peroxisome proliferator--activated receptor alpha/gamma dual agonist ameliorates dyslipidemia and insulin resistance in prediabetic rhesus monkeys.
    Ding SY; Tigno XT; Braileanu GT; Ito K; Hansen BC
    Metabolism; 2007 Oct; 56(10):1334-9. PubMed ID: 17884441
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Atorvastatin and fenofibrate have comparable effects on VLDL-apolipoprotein C-III kinetics in men with the metabolic syndrome.
    Chan DC; Watts GF; Ooi EM; Ji J; Johnson AG; Barrett PH
    Arterioscler Thromb Vasc Biol; 2008 Oct; 28(10):1831-7. PubMed ID: 18566295
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Lipid and apolipoprotein levels and distribution in patients with hypertriglyceridemia: effect of triglyceride reductions with atorvastatin.
    Le NA; Innis-Whitehouse W; Li X; Bakker-Arkema R; Black D; Brown WV
    Metabolism; 2000 Feb; 49(2):167-77. PubMed ID: 10690940
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Plasma Apolipoproteins Predicting the Occurrence and Severity of Diabetic Retinopathy in Patients With Type 2 Diabetes Mellitus.
    Zhang X; Nie Y; Gong Z; Zhu M; Qiu B; Wang Q
    Front Endocrinol (Lausanne); 2022; 13():915575. PubMed ID: 35937834
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Dual and pan-peroxisome proliferator-activated receptors (PPAR) co-agonism: the bezafibrate lessons.
    Tenenbaum A; Motro M; Fisman EZ
    Cardiovasc Diabetol; 2005 Sep; 4():14. PubMed ID: 16168052
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effects of simvastatin on plasma lipids and apolipoproteins in familial hypercholesterolemic swine.
    Hasler-Rapacz J; Kempen HJ; Princen HM; Kudchodkar BJ; Lacko A; Rapacz J
    Arterioscler Thromb Vasc Biol; 1996 Jan; 16(1):137-43. PubMed ID: 8548414
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Treatment of hypertriglyceridemia by two diets rich either in unsaturated fatty acids or in carbohydrates: effects on lipoprotein subclasses, lipolytic enzymes, lipid transfer proteins, insulin and leptin.
    Pieke B; von Eckardstein A; Gülbahçe E; Chirazi A; Schulte H; Assmann G; Wahrburg U
    Int J Obes Relat Metab Disord; 2000 Oct; 24(10):1286-96. PubMed ID: 11093290
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Lipoprotein distribution of apolipoprotein C-III and its relationship to the presence in plasma of triglyceride-rich remnant lipoproteins.
    Marcoux C; Tremblay M; Fredenrich A; Davignon J; Cohn JS
    Metabolism; 2001 Jan; 50(1):112-9. PubMed ID: 11172484
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Very low density lipoprotein metabolism and plasma adiponectin as predictors of high-density lipoprotein apolipoprotein A-I kinetics in obese and nonobese men.
    Chan DC; Barrett PH; Ooi EM; Ji J; Chan DT; Watts GF
    J Clin Endocrinol Metab; 2009 Mar; 94(3):989-97. PubMed ID: 19116237
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effect of weight loss on markers of triglyceride-rich lipoprotein metabolism in the metabolic syndrome.
    Chan DC; Watts GF; Ng TW; Yamashita S; Barrett PH
    Eur J Clin Invest; 2008 Oct; 38(10):743-51. PubMed ID: 18837799
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Apolipoproteins C-III and A-V as predictors of very-low-density lipoprotein triglyceride and apolipoprotein B-100 kinetics.
    Chan DC; Watts GF; Nguyen MN; Barrett PH
    Arterioscler Thromb Vasc Biol; 2006 Mar; 26(3):590-6. PubMed ID: 16410456
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The dual PPARalpha/gamma agonist tesaglitazar blocks progression of pre-existing atherosclerosis in APOE*3Leiden.CETP transgenic mice.
    van der Hoorn JW; Jukema JW; Havekes LM; Lundholm E; Camejo G; Rensen PC; Princen HM
    Br J Pharmacol; 2009 Apr; 156(7):1067-75. PubMed ID: 19220285
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.